Determine the necessary mass, volume, or concentration for preparing a solution.
This is a demo store. No orders will be fulfilled.
| SKU | Size | Availability |
Price | Qty |
|---|---|---|---|---|
|
C408052-1ml
|
1ml |
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
|
$39.90
|
|
5-HT2 Selective Inhibitors | Agonists | Antagonists | Modulators
| Synonyms | HF 1854, LX 100-129 | 8-chloro-11-(4-methyl-1-piperazinyl)-5H-dibenzo[b,e][1,4]diazepine |
|---|---|
| Specifications & Purity | Moligand™, 10mM in DMSO |
| Biochemical and Physiological Mechanisms | Clozapine (HF 1854, LX 100-129) is an atypical antipsychotic drug by acting as a 5-HT antagonist, used in the treatment of schizophrenia. |
| Storage Temp | Store at -80°C |
| Shipped In |
Ice chest + Ice pads This product requires cold chain shipping. Ground and other economy services are not available. |
| Grade | Moligand™ |
| Action Type | AGONIST, ALLOSTERIC MODULATOR, ANTAGONIST, GATING INHIBITOR |
| Mechanism of action | Dopamine D2 receptor antagonist |
| Product Description |
Information Clozapine (HF 1854, LX 100-129) is an atypical antipsychotic drug by acting as a5-HTantagonist, used in the treatment of schizophrenia. Clozapine (10, 20 mg/kg) significantly increases the number of Fos-positive neurons in the nucleus accumbens, medial prefrontal cortex and lateral septal nucleus. Clozapine induces zif268 but not c-fos mRNA in rat striatum, while Haloperidol induces c-Fos-like immunoreactivity in the caudate-putamen. Clozapine is more selective for D4 receptors compared to D2 receptors. Clozapine is a mixed but weak D1/D2 antagonist. Clozapine produces a marked facilitation (300-400%) of NMDA-evoked responses in a concentration-dependent manner with EC50 of 14 nM. Clozapine, but not haloperidol, produces bursts of excitatory postsynaptic potentials (EPSPs), which are blocked by glutamate receptor antagonists, suggesting that these EPSPs are the result of increasing release of excitatory amino acids. Clozapine is a full agonist at the muscarinic M4 receptor (EC50 = 11 nM), producing inhibition of forskolin-stimulated cAMP accumulation. Clozapine potently antagonizes agonist-induced responses at the other four muscarinic receptor subtypes. In vivo Clozapine\xa0exhibits an "inverted-U" shaped dose-response\xa0curve, reversing the\xa0apomorphine-induced loss of prepulse\xa0inhibition\xa0(PPI) at low doses but not at high doses in the rats.\xa0Clozapine\xa0decreases PPI independent of\xa0apomorphine\xa0treatment in the rats.\xa0 cell lines:LNCaP cells, PC3 cells Concentrations: Incubation Time: Powder Purity:≥99% |
| ALogP | 3.422 |
|---|---|
| hba_count | 1 |
| HBD Count | 1 |
| Rotatable Bond | 1 |
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Smiles | CN1CCN(CC1)C2=NC3=C(NC4=C2C=CC=C4)C=CC(=C3)Cl |
|---|---|
| Molecular Weight | 326.82 |
| Reaxy-Rn | 764984 |
| Reaxys-RN_link_address | https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN=764984&ln= |
| Solubility | Solubility (25°C) In vitro DMSO: 37 mg/mL (201.53 mM); Water: 37 mg/mL (201.53 mM); Ethanol: 37 mg/mL (201.53 mM); |
|---|---|
| DMSO(mg / mL) Max Solubility | 65 |
| DMSO(mM) Max Solubility | 198.89 |
| Water(mg / mL) Max Solubility | <1 |
| 1. Huanhuan Yang, Cong Liu, Chuanhong Zhu, Yan Zheng, Juan Li, Qianyun Zhu, Hao Wang, Xiangming Fang, Quan Liu, Man Liang, Zilong Liu. (2023) Determination of ten antipsychotics in blood, hair and nails: Validation of a LC–MS/MS method and forensic application of keratinized matrix analysis. JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 234 (115557). |
| 2. Xinding Yao, Zhenwei Wang, Yue Geng, Hongkun Zhao, Elaheh Rahimpour, William E. Acree, Abolghasem Jouyban. (2022) Hirshfeld surface and electrostatic potential surface analysis of clozapine and its solubility and molecular interactions in aqueous blends. JOURNAL OF MOLECULAR LIQUIDS, 360 (119328). |
| 3. Jiajing Xin, Saihong Yan, Xiangsheng Hong, Huan Zhang, Jinmiao Zha. (2021) Environmentally relevant concentrations of clozapine induced lipotoxicity and gut microbiota dysbiosis in Chinese rare minnow (Gobiocypris rarus). ENVIRONMENTAL POLLUTION, 286 (117298). |
| 4. Yi Gong, Yueru Wang, Zibo Huang, Jiao sha, Yu Li, Tao Li, Baozeng Ren. (2021) Solubility, solvent effect, molecular simulation and thermodynamic properties of clozapine in twelve pure solvents. JOURNAL OF CHEMICAL THERMODYNAMICS, 158 (106398). |
| 5. Kai Hu, Tiantian Pang, Yanmei Shi, Jiamin Cheng, Yanjie Huang. (2020) Facile preparation of a magnetic porous organic frameworks for highly sensitive determination of eight alkaloids in urine samples based UHPLC-MS/MS. MICROCHEMICAL JOURNAL, 157 (105048). |
| 6. Juan Cui, Huaping Wang, Zhiqiang Zheng, Qing Shi, Tao Sun, Qiang Huang, Toshio Fukuda. (2018) Fabrication of perfusable 3D hepatic lobule-like constructs through assembly of multiple cell type laden hydrogel microstructures. Biofabrication, 11 (1): (15016). |
| 7. Danyi Lu, Qian Xie, Baojian Wu. (2017) N-glucuronidation catalyzed by UGT1A4 and UGT2B10 in human liver microsomes: Assay optimization and substrate identification. JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 145 (692). |